Chiasso, Switzerland, May 7, 2025 – Dipharma SA is pleased to announce the introduction of a new and innovative packaging solution to protect its Sapropterin products, designed specifically for far east countries.

This solution aligns with the highest standards reached by our medicines in the European markets , featuring a state-of-the-art customized tray system designed to provide exceptional protection and preservation of the product.

Developed in collaboration with Körber, a global leader in pharmaceutical technology, the new packaging—called “Safepack”— represents a new benchmark in product protection and quality.

The Safepack features a double-walled design with an air chamber on all six sides, providing enhanced cushioning and robust protection for the bottles containing Sapropterin soluble tablets. This pioneering design ensures optimal preservation of the tablets’ integrity, safeguarding them against potential damage during transportation and storage.

“With the introduction of Safepack, we reaffirm our commitment to innovation and the provision of high-quality solutions for patients. Packaging plays a pivotal role in ensuring our medicines reach patients in perfect condition,” said Fabio Cannata, General Manager at Dipharma SA. “Our collaboration with Körber highlights the transformative power of innovation and partnership in advancing pharmaceutical packaging.”

“The testing process – said Claudia Langjahr, Packaging Development Engineer at Körber – involved dropping the package multiple times to simulate potential real-world accidents. And the results were impressive: even under the most extreme conditions, the customized Safepack was able to protect the tables from any kind of breakage”

For more information, please refer to the Case Study developed by Dipharma and Körber (click here).

About Dipharma

Dipharma SA is a Swiss specialty pharmaceutical company, developing high quality, improved, medicines for rare diseases. Dipharma SA is part of a third-generation group of family-owned companies that have grown to a global presence.

With a portfolio of generic orphan products for the treatment of Hyperphenylalaninemia, Gaucher Disease, Hereditary Tyrosinemia Type 1, Urea Cycle Disorders and others, Dipharma SA provides improved solutions for patients affected by inborn metabolic diseases at an affordable cost and with a global reach.

For more information, please visit www.dipharma.ch

About Körber

Körber is an international technology group with more than 100 locations worldwide, united by a common goal: transforming entrepreneurial thinking into customer success and shaping technological change. Operating in the Business Areas of Digital, Pharma, Supply Chain, and Technologies, the group provides products, solutions, and services designed to inspire. A fast and seamless approach to customer needs and idea execution ensures that innovations create added value. Increasingly, the focus is on building ecosystems that address the challenges of today and tomorrow. Körber AG serves as the holding company of the Körber Group.

For more information, please visit: https://www.koerber.com/en/pharma

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. Dipharma SA operates respectfully of any third-party IP rights and/or regulatory exclusivities that may exist in each specific country. This press release may contain information on pharmaceuticals that are not currently approved or available in your country or region.